Erlotinib in salvage treatment of patients with advanced non-small cell lung cancer: results of an expanded access programme in Poland

AIM OF THE STUDY: Erlotinib and gefitinib are reversible EGFR-TKI administered orally. Results of the phase III study JBR.21 proved the clinical efficacy of erlotinib-based regimens as second- or third-line treatment of advanced NSCLC. We analyze efficacy of treatment with erlotinib in patients suff...

Descripción completa

Detalles Bibliográficos
Autores principales: Kowalski, Dariusz M., Krzakowski, Maciej, Ramlau, Rodryg, Jaskiewicz, Piotr, Janowicz-Żebrowska, Anna
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Termedia Publishing House 2012
Materias:
Original Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3687401/
https://www.ncbi.nlm.nih.gov/pubmed/23788872
http://dx.doi.org/10.5114/wo.2012.28798

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3687401/
https://www.ncbi.nlm.nih.gov/pubmed/23788872
http://dx.doi.org/10.5114/wo.2012.28798

Ejemplares similares